Pure Global
NCT06278766

A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration

Mass Balance Study of [14C] ABBV-552 in Healthy Male Volunteers Following Single Oral Dose Administration
AbbVie·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Volunteer
Drug/Device/Intervention
ABBV-552
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
AbbVie
Location
Madison, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Feb 21, 2024
End date
Apr 19, 2024
Enrollment
8 participants
Primary outcome

Number of Participants with Adverse Events (AEs),Maximum observed concentration (Cmax) of ABBV-552,Time to Cmax (peak time, Tmax) of ABBV-552,Terminal phase elimination rate constant (λz) of ABBV-552,Terminal phase elimination half-life (t1/2) of ABBV-552,Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration (AUCt) of ABBV-552,Area under the plasma concentration-time curve (AUC) from time 0 to infinite time (AUCinf) of ABBV-552,Amount of ABBV-552 excreted in the urine over the sampling period (Aeu),Percent of ABBV-552 excreted in the urine,Renal clearance ABBV-552 (CLr),Amount of ABBV-552 excreted in the feces over the sampling period (Aef),Percent radioactivity excreted in the feces

Summary

The purpose of this study is to evaluate mass balance, pharmacokinetics and safety of [14C]
 ABBV-552 in healthy, male volunteers following administration of a single oral dose.

ICD-10 classifications
Healthy person accompanying sick personRoutine general health check-up of armed forcesPersons encountering health services in other circumstancesPersons encountering health services in other circumstancesPerson encountering health services in unspecified circumstances
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06278766
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06278766 through Pure Global AI's free database. This Phase 1 trial is sponsored by AbbVie and is currently Recruiting. The study focuses on Healthy Volunteer. Target enrollment is 8 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.